Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-Blind, Randomized, Parallel Group Study.

Trial Profile

Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-Blind, Randomized, Parallel Group Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms MACS
  • Sponsors AstraZeneca; Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 04 May 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top